These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1176 related articles for article (PubMed ID: 11413351)

  • 1. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
    van der Woude HJ; Winter TH; Aalbers R
    Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
    Lipworth BJ; Aziz I
    J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction.
    Politiek MJ; Boorsma M; Aalbers R
    Eur Respir J; 1999 May; 13(5):988-92. PubMed ID: 10414394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relief of dyspnoea by beta2-agonists after methacholine-induced bronchoconstriction.
    van der Woude HJ; Postma DS; Politiek MJ; Winter TH; Aalbers R
    Respir Med; 2004 Sep; 98(9):816-20. PubMed ID: 15338791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onset of relief of dyspnoea with budesonide/formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a double-blind, placebo-controlled study.
    Jonkers RE; Bantje TA; Aalbers R
    Respir Res; 2006 Dec; 7(1):141. PubMed ID: 17144916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unaltered perception of dyspnoea during treatment with long-acting beta2-agonists.
    van der Woude HJ; Aalbers R
    Eur Respir J; 2001 Aug; 18(2):269-71. PubMed ID: 11529283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol.
    Kalra S; Swystun VA; Bhagat R; Cockcroft DW
    Chest; 1996 Apr; 109(4):953-6. PubMed ID: 8635376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction.
    van der Woude HJ; Boorsma M; Bergqvist PB; Winter TH; Aalbers R
    Pulm Pharmacol Ther; 2004; 17(2):89-95. PubMed ID: 15123230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism.
    Lipworth BJ; Dempsey OJ; Aziz I
    Chest; 2000 Aug; 118(2):321-8. PubMed ID: 10936119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo effect of albuterol on methacholine-contracted bronchi in conjunction with salmeterol and formoterol.
    Aziz I; Lipworth BJ
    J Allergy Clin Immunol; 1999 May; 103(5 Pt 1):816-22. PubMed ID: 10329815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics.
    Wong AG; O'Shaughnessy AD; Walker CM; Sears MR
    Eur Respir J; 1997 Feb; 10(2):330-6. PubMed ID: 9042628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma.
    Higham MA; Sharara AM; Wilson P; Jenkins RJ; Glendenning GA; Ind PW
    Thorax; 1997 Nov; 52(11):975-80. PubMed ID: 9487346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists.
    van Veen A; Weller FR; Wierenga EA; Jansen HM; Jonkers RE
    Pulm Pharmacol Ther; 2003; 16(3):153-61. PubMed ID: 12749831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial.
    Haney S; Hancox RJ
    Respir Res; 2005 Sep; 6(1):107. PubMed ID: 16168062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
    Palmqvist M; Persson G; Lazer L; Rosenborg J; Larsson P; Lötvall J
    Eur Respir J; 1997 Nov; 10(11):2484-9. PubMed ID: 9426083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline.
    Richter K; Janicki S; Jörres RA; Magnussen H
    Eur Respir J; 2002 May; 19(5):865-71. PubMed ID: 12030726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: a randomised, double-blind, cross-over study.
    Aalbers R; Boorsma M; van der Woude HJ; Jonkers RE
    Respir Res; 2010 May; 11(1):66. PubMed ID: 20509942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid onset of tolerance to the bronchoprotective effect of salmeterol.
    Bhagat R; Kalra S; Swystun VA; Cockcroft DW
    Chest; 1995 Nov; 108(5):1235-9. PubMed ID: 7587422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients.
    Palmqvist M; Ibsen T; Mellén A; Lötvall J
    Am J Respir Crit Care Med; 1999 Jul; 160(1):244-9. PubMed ID: 10390407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.